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INTRODUCTION
Epilepsy is the commonest neurological disorder seen in clinical
practice. The incidence of epilepsy is 44 per 100,000 person years. The
incidence in females, is 41 per 100,000 person years, and for males is 49 per
100,000 person years. [1,2] The prevalence of epilepsy was slightly higher in
males than females (6.5 vs 6.0 per 1000 persons) in the epileptic study
reported at Rochester. In India people affected by epilepsy are more than 10
millions, constituting a prevalence of about 1% of the population. There are
2.73 million women with epilepsy in India and about 52% of them are in the
reproductive age group.
EFFECTS OF HORMONE ON EPILEPSY
Epilepsy can occur in women during any part of their lifetime, either at
puberty, pregnancy or menopause. Epilepsy in women is affected by a number
of factors. Sex differences and the effects of steroid hormones, such as
androgens, estrogens, and progestogens, influence seizures [3]. Early
organizational and later activational effects of these hormones can amplify
sex/gender differences in the expression of some seizure disorders which are
modulated by androgen. Estrogens can activate seizures and interictal
discharges when directly applied to the cerebral cortex or infused
intravenously. Estrogen acts as a glutamate agonist in the hippocampus and its
actions are mediated due to altered calcium permeability of the cell membrane,
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and reduction of chloride influx through the gamma-aminobutyric acid
(GABA)-A receptor. Progesterone decreases cortical excitability, by
enhancing GABA effects, and increases electroshock seizure threshold in
experimental models.
Cortical excitability is also known to be affected by pituitary and
gonadal hormones. An marked increase in pituitary luteinizing hormone (LH),
follicle-stimulating hormone (FSH),and their cyclic fluctuations,occurs with
the onset of menarche. They also fluctuate during pregnancy, the
perimenopausal period, and with the introduction of oral contraceptives, and
hormone replacement therapy. This hormonal increase occuring during
menarche, contributes to the onset of epilepsy during this period . There is
marked interindividual variability in response to these hormonal alterations
resulting in changes in epilepsy and seizure threshold. Seizure types are
exacerbated by different hormonal patterns
Catamenial epilepsy is due to exacerbation in seizures with the onset
of menstrual cycle.[3,4] True catamenial epilepsy requires reproducible and
consistent increase or change in character of seizures at the same point in a
regular menstrual cycle. Anovulatory cycles can make the relationship of
seizure to hormones difficult to discern. Epilepsy expressed at this time may
in part due to this increase in estrogen, or cyclic increases in estrogen relative
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to progesterone which appear to act as a likely trigger for breakthrough
seizures.
PREGNANCY HORMONAL ALTERATIONS
There is a marked increase in the levels of estrogen and progesterone as
well as an alteration in the metabolism of hormones and antiepileptic drugs.[3]
Menopause may occur earlier in women with epilepsy than in the
general population. Onset of menopause was earlier in women with a high
seizure rate.[5] Seizures may disrupt the hypothalamic pituitary function or
alter neutrally mediated trophic effects on the ovary.
Infertility
Women with epilepsy show reduced fertility in comparison with
women in the general population. At least one third of menstrual cycles in
women with generalized seizures are anovulatory. PCOS ,or hypothalamic
amenorrhea has been found in 12.5% of women with TLE whereas it occurs in
1.5% of general population. [3]
EFFECTS OF EPILEPSY ON THE HORMONES
Fluctuations in the levels of luteinizing hormone (LH) and pulsatile
release of prolactin and sex steroids have been observed in temporal relation to
some seizures. [6]
 4
 The type of epilepsy may also have a significant influence on
reproductive hormones and function. The temporal limbic system plays a vital
role in reproductive endocrine regulation and in sexual function .In patients
with medial temporal lobe epilepsy there is disruption of the hypothalamic
pituitary axis and altered gonadal function.(6)
Anti-epileptic drugs (AEDs) enables 60% of them to remain seizure-
free, another 20% to achieve partial control of seizures, but the remaining 20%
are unresponsive to AEDS .Pregnancy influences seizures by causing an
increase in seizure frequency in one fourth, decreases in another one fourth,
and no change in the seizure in the remaining half. Each and every pregnancy,
even under excellent, care is risky at times. Most patients are unwilling to
accept the side effects of antiepileptic drugs, due to fear and misperceptions
about the facts related to pregnancy, epilepsy, and antiepileptic drugs
Therefore it is the prime duty of every doctor treating women with
epilepsy(WWE) who are planning to become pregnant or having become
pregnant to explain the risks associated with the disorder and the drugs used
for treatment .Patients should be ensured that they can be ensured a safe
pregnancy and delivery by stringent care and monitoring.
Patients must be informed that untreated seizures by themselves may
increase the risk of birth defects by (Annegers et al.) (7) who also separated
the effects of AEDs from those of seizures during pregnancy. Patients should
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bemade aware of the fact that under the best of circumstances,any pregnancy
may carry a 1-2% risk of having an offspring with a malformation and that, the
mother with a seizure during pregnancy may double that risk. [7]
Many patients are aware that AED usage during pregnancy increases the
risk of malformations and it is not uncommon for patients to stop the AEDs
as they plan their pregnancy. Clinical experience and circumstantial evidence
suggest that WWE who have uncontrolled seizures during pregnancy have a
significantly increased (up to tenfold) morbidity and mortality as compared to
the general population.(8,9) Patients should be advised that stopping AEDs
treatment prior to pregnancy is harmful to both the mother and child in those
presenting with active seizure disorder.
Most of the WWE, will require long term treatment with antiepileptic
drugs (AEDs) to prevent seizures. Though the interactions between epilepsy
and pregnancy are multiple, it is the untoward effect of AEDs on the
developing fetus that is a cause of major concern to the child bearing
individual.
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REVIEWOF LITERATURE
EFFECTS OF PREGNANCY ON EPILEPSY.
Approximately 1.1 million women with epilepsy are of child bearing
age group. Preconception counseling is necessary for women with epilepsy
and is a time to educate and inform these patients about optimal care before,
during, and after pregnancy. It should be acknowledged that once women
reaches the reproductive age that pregnancy is possible, whether planned or
not, and preconception counseling should be done very frequently during
routine neurological visits.
Pregnancy in WWE is associated with increased maternal risks and
adverse neonatal outcomes compared to the general population. Concensus
guidelines by the American academy of neurology (25) has emphasized
minimizing the associated risks by reducing the AED dosage and by folic acid
intake.But there are no guidelines regarding the best management once a
women is pregnant.
SEIZURES IN PREGNANCY
The assessment of a women’s seizure activity is imperative when
considering reproductive options. [10,11] It is recognized that seizure activity
increases in pregnancy in about a quarter , has no change in about a half.
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Investigatorsevaluating the course of epilepsy during pregnancy have shown
an increase in 24%[12], a decrease in 23%, and no change in 53%. Recent
studies by (Vadja et al) [13] has shown that being seizure free prior to
pregnancy is associated with seizure freedom during pregnancy. The risk for
status epilepticus during pregnancy is about 1-2%. Status epilepticus is known
to cause increased risk of maternal morbidity and mortality and fetal mortality
in older studies but this risk appears to be substantially lower with
improvements made in treatment (EURAP Study Group). [14] Seizures during
pregnancy imposes risk to both the mother and fetus, convulsions may cause
lactic acidosis and transient increase in uterine pressure and blood flow. It is
recommended for the patient to be placed in the left lateral decubitus position
to facilitate fetal blood flow and reduce the possibility of aspiration Barrett and
Richenset al. [15]
The onset of structural and metabolic changes may precipitate new onset
seizures during pregnancy. Changes in the pattern of seizure occurrence would
include structural causes like intracranial hemorrhage, cerebral venous sinus
thrombosis, and ischemic stroke, hyperemesis gravidarum, acute hepatitis
(due to fatty liver of pregnancy or viral hepatitis) metabolic disorders such as
acute intermittent porphyria ,infections like malaria and gestation induced
hypertension.
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 Risk for deterioration in seizure control has been associated with focal
onset epilepsy, polytherapy, monotherapy with oxcarbazepine [OXC] or
lamotrigine [LTG], and poor compliance associated with lack of prepregnancy
planning. [14,15] There is intraindividual variability in patterns of seizure control
in successive pregnancies, and interindividual variability among WWE. [16]
During pregnancy, AED dose may require an modification, an increase
in some patients, if free drug levels fall, or if the semiology of seizures
changes. It is important to maintain good compliance with AEDs throughout
pregnancy to avoid relapse of seizures, especially because some patients may
discontinue AEDs due to a perceived risk, by themselves without discussing it
with their treating physicians. [14]
Seizures are most likely to occur in the first trimester and in the
peripartum period. Nearly 5% of WWE, will have peripartum seizures,
representing a three-fold increase compared to the rest of pregnancy. This is
due to factors such as poor compliance, dehydration, decreased oral intake, and
intercurrent medications. [12,14]
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Factorsinfluencing seizure control during pregnancy
Gestation induced alteration in AED pharmacokinetics
Knowledge of the pharmacokinetics of the different AEDs during
pregnancy is necessary for the treating physician to appropriately anticipate
and implement necessary medication changes (Perucca). [6,15,17] A major factor
is decreased binding to plasma proteins,which causes lower total plasma
levels, but generally free (unbound) and active drug concentrations remain
stable.
PHYSIOLOGICAL CHANGES DURING PREGNANCY:
ITS EFFECTS ON DRUG DISPOSITION
PARAMETERS CONSEQUENCES
Total body water extracellular fluid Altered drug metabolism
 Fat stores  Elimination of lipid soluble drugs
Cardiac output Hepatic blood flow leading to 
elimination
Renal blood flow and glomerular
flow rate altered CYP 450 activity and
UGT activity
Renal clearance of unchanged
drug,altered systemic absorption
andhepatic elimination
Maternal albumin Altered free fraction,increased
availability of drug for hepatic
excretion.
 10
Psychological
• Noncompliance with medications.
• Increased stress and anxiety.
Physiologic
• Sleep deprivation
Hormonal
• Increased estrogen / progesterone ratio
• Increased human chorionic gonadotropin levels in first trimester
Battino et al [18] found that total and unbound plasma concentrations of
Phenobarbital decline throughout pregnancy by nearly 50% .Yerby et al. [19]
reported no significant changes in free valproate levels, although total levels
declined significantly. They also reported a 42% decrease in total plasma
carbamazepine levels along with a 22% decrease in free carbamazepine.
However, Tomson et al [15] found much less reduction in levels. Both these
groups found a 40% decrease in total phenytoin levels and a 20%decrease in
free levels.
Levels of newer AEDs like lamotrigine are dramatically affected during
pregnancy.By the 32nd week of gestation, clearance may increase more than
threefold (Pennell et al; Tran et al.)[20,21] There is a greater decrease in drug
levels compared to older AEDs and may cause increased seizure frequency or
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severity, which can prevented by escalating doses. If raised during,
pregnancy, the dose needs to be reduced after delivery, to reduce postpartum
toxicity .The pharmacokinetics of the other newer AEDs on the course of
pregnancy is not very clear.
PERIPARTUM SEIZURES
EFFECTS ON THE MOTHER
Three percent of women with epilepsy are at risk of developing seizures
at delivery and in the next following 24 hours.This may be due to failure to
take AEDs, lack or inadequate sleep, or impaired drug absorption. Women
with generalised epilepsies are at increased risk during or immediately after
delivery, than those with partial siezures if the AED concentrations are
maintained sub-therapeutically due to inadequate drug dosage. Status
epilepticus is associated with high a maternal and infant mortality and should
be managed aggressively. Prophylactic use of clobazam is advocated during
peripartum period.
PLACENTAL FACTORS AFFECTING AED TRANSPORT
In case of placental transfer there is an increasing awareness of drug
transporters or efflux proteins that regulate AED passage into the fetal
circulation. Placental drug transporters have increased blood brain barrier
expression especially in those with refractory epilepsy. Though the placenta
expresses many CYP 450 (including CYP1A1,2E1,3A4,3A7,4B1) and uridine
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diphosphonate glucoronyl transferase isoenzymes, AED excretion via this
route minimally affects the foetus
Transporters like MDR I , multidrug resistance protein 1 and 2 (MRP 1,
MRP 2 ), and monocarboxylate transports are located at the apical membrane
of the syncytiotrophoblast where they extrude drugs from the fetal circulation
back into the maternal one (Atkinson et al ; Syme et al.)[22,23]
EFFECTS ON THE INFANT
Some AEDs like primidone, phenobarbitone, and the benzodiazepines,
are sedating and few infants manifest drug withdrawal symptoms in the first
few days of neonatal life. Withdrawal seizures are rare, but are said to be most
common with phenobarbitone.
PROBLEMS IN FEEDING AND DRUG WITHDRAWAL
Virtually all AEDs are excreted in breast milk, but only in low
concentrations. The amount of drug received by the infant is less than that
what the fetus receives during pregnancy. The higher the protein binding
capacity of the AED, the least will be transferred from plasma to breast milk.
The elimination half-life of most of the AEDs tends to be prolonged in
neonates.
Breast feeding should be encouraged in all women with epilepsy taking
AEDs.. Newer drugs and drugs like LTG, PHT, PB, primidone[24,25] should be
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introducedwith great care in the postpartum period to breast feeding women
as they are excreted in the breast milk. For the AEDs ethosuximide,
levetiracetam, Lamotrigine, and zonisamide, there is a potential for significant
breast milk concentrations, however there are no safe guidelines on whether
lactation is safe. In these circumstances the lowest dose of AED to achieve
seizure control is given, and the mothers are advised to report any excessive,
sedation, irritability, feeding difficulty ,or failure to gain weight. If this occurs
then formula feeds are instituted,or discontinuiation of lactation is needed..
EPILEPSY IN THE POSTPARTUM PERIOD
Mothers with uncontrolled epilepsy should not be left alone with
babies, for it presents a greater risk to infants and toddlers than to the
fetus.The infant may drop down from the mother’ s hand at the start of the
seizure if left unattended, more common in juvenile myoclonic epilepsy
patients.They should be carefully supported by family members during all
activities of the mother, even during nursing and bathing of babies. Dosage
adjustments of AEDs should be done in the postpartum period if they were
increased during antenatal period.
EFFECTS OF EPILEPSY ON PREGNANCY
The data from Indian epileptic registry from kerala by Sanjeev Thomas
et al [26,27] reported an increased incidence of, spontaneous abortions as more
common in epileptic women. Borthenet al from Norway found that epileptic
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pregnant women consuming AEDs had a 1.5-fold increased risk of mild
preeclampsia, two-fold increased risk of late vaginal bleeding, a 1.5-fold
increased risk of gestational hypertension and delivery before week 34 weeks
of gestation. Epileptic pregnant women not on AEDs had no increased risk
of antenatal complications compared to the general population. A recent study
showed that carbamazepine in particular was associated with a higher risk for
pre-eclampsia. AED-induced folate deficiency and alteration in the
metabolism of vitamin K-dependent blood clotting factors have been
suggested as possible causes of vaginal bleeding in late pregnancy.
OBSTETRICAL RISKS AND MANAGEMENT DURING LABOUR
For the most part, patients with seizure disorders do well in pregnancy.
Richmond et,al [28] reported on 414 births from 314 women from 1978 to 2000
with seizure disorder, found an increased risk for nonproteinuric hypertension,
and induction of labour they found that these patients had fewer instrumental
vaginal deliveries. Less than one antenatal seizure did not have an effect on
antenatal outcome if treated appropriately. There was no difference in other
complications of pregnancy and only a small increase in caesarean section
rates.
Studies have shown a clearly increased risk of caesarian section in
WWE Pilo et al; [29] and no studies show an absence of increased risk. The
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overallrisk is around twofold; however, the reason for the increased caesarian-
section rate is unclear.
Patients with epilepsy should be followed up closely for signs and
symptoms of pregnancy complications besides having their antiepileptic drug
serum concentrations monitored serially throughout pregnancy. For example,
serial growth scans are done to rule out growth abnormalities such as
intrauterine growth retardation, congenital abnormalities, placental
insufficiens, and to assess the adequacy of amniotic fluid. Blood pressure
should be monitored frequently for signs and symptoms of preeclampsia.
Likewise, they should be watched for signs and symptoms of preterm
labour.[27]
EFFECT OF EPILEPSY ON THE FOETUS
The untoward effects of epilepsy and AEDs on the fetus are
(1) anthropometric changes, (2) physiological changes, (3) teratogenic effects,
and (4) long-term cognitive effects. [9] Several studies have shown that infants
of WWE have low birth weight and are small for gestational age. A large
population-based study in Norway had shown that infants of WWE exposed to
AEDs in utero had higher risk of preterm birth, low birth weight, intrauterine
growth retardation, and smaller head circumference at birth. Similar findings
in birth weight were observed in neighboring Sweden also.[30] Head
circumference at birth in infants of WWE is influenced by the paternal head
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circumference,maternal AED exposure and several other factors. Apgar score
at birth is a reliable measure of the physiological status of the newborn.
Population-based studies in Norway had revealed that infants exposed to
AEDs in utero of mothers with epilepsy had lower Apgar score than the
controls.
MALFORMATIONS
The occurrence and degree of an abnormality (i.e., deviation from the
norm) bear close relationship with time of exposure, the “critical period.”
Insults at very early stages of development (first few hours or days) are more
likely to affect primordial cell lines responsible for organogenesis and result in
significant abnormalities or absence of all its derivatives. These are more often
lethal defects.
In neurological parlance, the “ anatomic critical period “ is the time of
occurrence of a given malformation (i.e., neural tube defects occur between 30
and 31 days).The practice of stopping AEDs by the second or third weeks of
pregnancy to prevent early malformations is usually not recommended
because of the potential to increase the risk of seizures. All pregnant patients
should be made aware of these facts and any concerns about AED-induced
malformations should be addressed prior to pregnancy.
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Majorcongenital malformations(MCM) are defined as a physical defect
requiring medical or surgical intervention and causing major functional
disturbance. Minor malformation do not require any treatment and not life
threatening.
System Malformations
CVS TOF, ASD, VSD, PDA, PA, Single ventricle
Craniofacial Cleft lip, cleft palate
Skeletal Club foot, hip dislocation, etc.
CNS Neural tube defects
GIT EA, CHPS, omphalocele, hernia (diaphragm, inguinal,
umbilical)
GUT Renal agenesis, hydronephrosis, hypospadias,
undescended testes
Others
Total
Congenital malformations can affect any organ and the risk is doubled in
epileptic women by Vadja et al, Holmes et al, meador et al. [31,32,33]
Developmental delay and cases of fetal anticonvulsant syndrome, where
there was a combination of dysmorphic features but no major defects as
defined above were coded as minor structural malformations, although they
were significant defects in themselves.
There is an increased risk of malformation in WWE exposed to AED,
than in those whom are not exposed. [33,34,37,38]
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Antiepileptictreatment and incidence of
major congenital malformations
DRUG USAGE INCIDENCE OF MAJORCONGENITAL MALFORMATIONS
Any antiepileptic drug 7.86%
Lamotrigine monotherapy 2.1%-2.9%
Carbamazepine monotherapy 2.0%-5.2%
Phenobarbital monotherapy 4.7%-6.5%
Phenytoin monotherapy 3.4%-10.5%
Valproic acid monotherapy 8.6%-16.7%
Untreated 0.8%-5.0%
General population 1.62%-2.2%
LATE EFFECTS DUE TO LATE EXPOSURE
Susceptibility to developmental abnormalities is not limited to the first
trimester of pregnancy. The central nervous system continues to grow and
changes continue during pregnancy. Agents that interfere with neurocognitive
development can do so throughout that period. In some cases, the
neurocognitive disorders can be as devastating as a malformation, on children
and families. SVP, PB, and Primidone can have adverse effects on CNS
development (Adab et al.; Meador et al.,) (47,35) Clinically,they are manifested
as small head circumference and attentional and learning deficits that may go
undetected until school years. Given the potentially serious cognitive
implications and the uncertainties in ascertaining causation, the use of valproic
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acid, phenobarbital, and primidone should,if at all possible, be avoided
throughout the duration of pregnancy.
EFFECTS ON AEDS ON LACTATION FETAL AND NEONATAL
EXPOSURE
Epileptic pregnant women can have healthy babies even with significant
placental exposure and can breast feed their babies safely with cautions.
Phenobarbital and primidone should be avoided in parents wishing to breast
feed. Significant breast milk concentrations are found to occur for. the AEDs
ethosuximide, levetiracetam, lamotrigine, topiramate and zonisamide;
however, there are no firm guidelines on whether lactation is safe.[24]
Indirect neonatal anticonvulsant exposure comes from certain situations.
First involuntary exposure occurs in utero through transplacental transfer in
mothers receiving anticonvulsants. The second is through ingestion of breast
milk containing anticonvulsant in mothers with epilepsy.
FACTORS INFLUENCING ANTICONVULSANT DISTRIBUTION TO
THE NEONATE
Many of the factors that determine placental and breastmilk transfer are
similar. The most common means by which drugs reach the neonate is by
passive diffusion. In such instances, the amount of drug that crosses a
membrane per unit of time is dependent on the difference in concentration of
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drug in the maternal and fetal or neonatal circulations, its physiochemical
properties, and the rapidity of maternal drug clearance. Lipid soluble,un-
ionized drugs with low molecular weights (less than 500Daltons) tend to
diffuse more readily andrapidly. Most AEDs tend to be either weak acids or
weak bases; therefore the drug’s pka and maternal/neonatal blood ph ratio
affects its relative ionization.
Because it depends on maternal diet, the extent of transfer can vary
across the course of a day or between days. AEDs with greater lipid solubility
tend to distributed more rapidly into breast milk. However distribution may not
be uniform across milk fractions. This is particularly true for mature milk,
hindmilk, and postfeed milk which tend to be of higher triglyceride content,
and therefore may contain higher concentrations of lipophilic AEDs[32].
NEONATAL PHARMACOKINETICS
Both gestational age and postnatal age affect the pharmacokinetics of
AEDs. Hepatic and renal elimination pathways are relatively immature,
making neonates prone to drug accumulation. While CYP2C9 is involved in
the elimination of phenytoin (PHT), CYP2C19 metabolizes both PHT and
pheobarbital (PB).Although there are subtle differences, examination of the
ontogeny of these enzyme subfamilies reveals that expression is reduced or
nonexistent in early fetal development and in neonates and increases during
infancy (McCarver and Hines).The phase II reactions relevant to epilepsy are
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catalysedby the UGTs.Lamotrigine (UGTIA4), valproate (VPA) (UGT2BI ),
and oxcarbazine (OXG) all are metabolized in various degrees by UGT
isoenzyme enzymes. This suggest that renally eliminated AEDs [particularly
LEV, gabapentine (GBP), pregabalin] may have prolonged elimination in
neonates (Perucca).[36] Total and free PHT readily distribute across the placenta
with a umbilical cord/ maternal concentration of 0.86-1.0 and 1.1-1.25,
respectively.
HAEMORRHAGIC DISEASE IN THE NEWBORN
Enzyme inducing AEDs can produce bleeding in the newborn
period.The risk of hemorrhage in neonates[35] born to women with epilepsy
who were taking enzyme inducing AEDs during pregnancy is also of great
concern. First described by VanCreveld and later delineated as a syndrome by
Mountain et al, it has now been associated with exposure to AEDs like PB,
primidone, PHT,CBZ, diazepam, amobarbital, and ethosuximide Prevalence
figures are as high as 30%, but appear to average 10%.Mortality is high (over
30%) because the child is often diagnosed in a state of shock due to internal
bleeding ). This is due a deficiency of vitamin K-dependent clotting factors II,
VII, IX, and X, in the newborn the maternal coagulation parameters being
normal. A prothrombin precursor, protein induced by vitamin K absence
(PIVKA), has been discovered in the serum of mothers taking AEDs. Assays
(blood tests) for PIVKA may permit prenatal identification of infants at risk
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for hemorrhage Prevention of neonate bleeding has only been evaluated in
studies where the newborns all received intramuscular vitamin K injections
1mg at birth.[40] Whether AEDs would be associated with increased rates of
hemorrhage in the newborn if this dose of vitamin K were not given remains
unclear. Nonetheless, vitamin K supplementation 10-20mg/day of oral vitamin
K during the last 2-4 weeks of pregnancy or 10mg intravenously during
labour) is suggested, but again , to prevent bleeding in newborn, but this has
been disproved in the latest study.[43]
MANAGEMENT OF EPILEPSY AND PREGNANCY
Women with epilepsy who take antiseizure medicines have successful
and unremarkable pregnancies the majority of the time.[43] Achieving adequate
seizure freedom is important for successful present and future pregnancies, as
it is highly predictive of seizure freedom during pregnancy. From data
obtained from the general population, vitamin supplementation in the form of
preconceptal folic acid intake is important to prevent birth defects, and in
epileptic women of child-bearing age should be encouraged to take folic acid
supplements daily. Vitamins supplementation is routinely used by women
planning pregnancy to ensure an adequate nutritional status. The inclusion of
vitamin supplementation is important for the prevention of fetal abnormality.
An early landmark large randomized, controlled trial evaluating vitamin
dietary supplementation beginning at least 28 days before conception until at
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least two menses were missed showed fewer malformations in the vitamin
supplemented group .
In addition, it was shown that there were no neural tube defects in the
vitamin supplemented group (Czeizel and Dudas)[40] Folic acid
supplementation appears to be of particular importance in the prevention of
neural tube defects.[41] It has been suggested that the incidence of major
congenital malformations may be increased where supplemental folic acid is
lacking (Vajda et al). (13,42)
All pregnant women should be offered screening for aneuploidy and/or
invasive diagnosis for chromosomal abnormalities (first trimester chorinic
villous sampling or second trimester genetic amniocentesis) in those at high
risk. There are several screening tests available for trisomy 13,18,and 21. The
most common of which is trisomy21 which is known as Down’s syndrome.
All of these aneuploidies increase in incidence as the women’s age
increases.The number of screening test available also has recently increased.
There is now a wide range of screening tests that combine first trimester
ultrasound (measurement of the fetal nuchal translucency, a sonolucent area at
the back of the fetus’s neck, and the presence or absence of the fetal nasal
bone) with first and second trimester maternal serum analysis. These include
first trimester placental associated pregnancy protein A [PAPP-A] and beta
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human chroinic gonadotrophin [hCG] and second trimester alpha fetoprotein
[MSAFP], inhibin,beta human chrionic gonadotrophin [BhCG], and estriol.
POSITIVE FAMILY HISTORY FOR MALFORMATION AND AEDS
Birth defects associated with use of medications often result from a
“multi-factorial inheritance” that is a combination of genetic make-up and
environmental exposure. In these cases, the individual may inherit one or more
genes that may increase the predisposition to birth defects if there is exposure
to certain environmental substances (such as AEDs).These individuals have
the genetic predisposition to a birth defect but may not develop it unless there
is exposure to particular substance during its early development
PROTOCOL FOR SCREENING OF CONGENITAL
MALFORMATIONS (Sanjeev Thomas etal) [27,29]
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PRENATALCARE:
During pregnancy, patients with seizure disorder for the most part
should be cared for like any other pregnant woman. The main differences are
that women with epilepsy are followed for their seizure activity and they may
be screened more intensively for fetal anomalies and cautioned about regular
AED intake.
PREGNANCY REGISTRIES:
The first pregnancy registry to monitor the safety of an AED was the
International Lamotrigine Pregnancy Registry,established by Burroughs
Welcome (now GlaxcoSmithKline) in 1992 (Cunnington and Tennis).
Subsequent AED pregnancy registries have been established by
independent academics groups or physician networks with the exception of the
gfcsingle drug Keppra Pregnancy Registry established in 2004 by UCB
Pharma (Magnus).The first multidrug AED pregnancy registry was initiated in
the UK in 1996 with educational grants from the Epilepsy Research
Foundation and various pharma companies. In addition to voluntary reports
from healthcare providers,women can directly enroll themselves in the UK
Epilepsy and Pregnancy Registry by telephoning a toll free number, though all
exposure and follow-up information is sought through the healthcare provider
(Russell et al.,). The multipharma company-sponsored North American
Antiepileptic Drug (NAAED) registry (also known as AED Pregnancy
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Registry),also established in 1996, followed collecting data across the United
States and Canada. This was the registry to rely solely on women directly
enrolling themselves with telephone interviews at enrolment, during pregnancy
and after delivery. Informed consent is additionally sought for medical record
review of outcomes (Holmes et al)[45]
The European Registry for Antiepliptic Drugs (EURAP)[14] was the last
multi AED registry to be informed in 2000 and grown to collect data in more
than 40 countries across Europe, Asia, and South America(Tomson et
al.,[14].Although an international registry offers many advantages, including
increased recruitment and greater generalizability, there are also significant
challenges in working across different healthcare settings. EURAP has met
these logistic challenges by working in a standardized protocol and ensuring a
consistent case definition with all defects reviewed by two protocol and
ensuring a consistent case definition with all defects reviewed by two
physicians at the central coordinating center.[14] The single country AED
pregnancy registries in the UK and Australia also report into EURAP.
In India the pregnancy registry is set up at kerala by Sanjeev Thomas.
Current regulatory guidance on establishing pregnancy registries offers
many methodological options while maintaining scientific rigor.
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 The key value of the pregnancy registry design is enrollment of women
exposed to the AED prior to conception and before the pregnancy outcome is
known. This increases the accuracy of the exposure reporting and reduces the
bias associated with retrospective reporting which can over represent more
severe and unusual cases. However, the prevalence and timing of antenatal
testing has made it increasingly difficult to recruit women into the registries
before they have any knowledge of fetal health.
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AIMOF THE STUDY
1. To study the alteration of seizure frequency during pregnancy.
2. To study the outcome of pregnancy in women with epilepsy.
3. To study the outcome of delivery in epileptic pregnant women.
4. To study the effect of epilepsy, and antiepileptic drugs on the
foetus and neonate.
5. To compare the outcomes of pregnancy in patients with or without
preconceptal counseling.
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MATERIALSAND METHODS
Material/selection of subjects: WWE in the reproductive age group who
were planning pregnancy or became pregnant were included in the study.
Patients with epilepsy attending epilepsy clinic at Institute of Neurology
Chennai and also RIOGH Egmore who were on antiepileptic drugs before and
during pregnancy were enrolled. All patients followed up through out the
course of pregnancy, and 3 months postpartum.
Exclusion criteria:
Patients with first episode of seizure during pregnancy, seizure due to
complications of diabetes or hypertension, or taking antiepileptic drugs after
the first trimester were excluded.
Methods/Analysis:
Demographic profile of patients obtained. Detailed history obtained
regarding the age of onset of epilepsy, duration, seizure type, frequency of
seizures dosage of AEDs, no of drugs. Detailed neurological examination was
done EEG, and MRI Brain done in all patients. Women and their families are
educated about the potential risks before they become pregnant. Risk factors
for adverse pregnancy outcomes like nutritional status (obese and underweight
women, or other intercurrent illnesses (diabetes, hypertension, urinary tract
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infection.) are assessed. To start risk reduction prior to conception in all
WWE.
The following maternal characteristics were analysed.
Seizure type during pregnancy is classified according to International
league against epilepsy . Whether there is increase in seizure frequency
during pregnancy.. Number of antiepileptic drugs and their individual
minimum and maximum dosages were noted.
Whether the patient is on monotherapy or polytherapy. In polytherapy
various drug complications are analyzed like (phenytoin+ carbamazepine,
phenytoin + carbamazepine+ sodium valproate, sodium valproate+
carbamazepine, sodium valproate+ phenytoin, sodium valproate+ phenytoin+
levetiracetam.
Correlation of drug dosage with foetal outcome.
The dosage of individual drugs required is analysed.Patient kept on the
lowest and effective dosage required to control seizures.
All patients are encouraged to take folic acid 5mg prior to conception
regularly. Women with epilepsy who were in the reproductive age group are
counseled to take folic acid in the preconceptual period regularly.
 31
 Obstetric data obtained from their antenatal records.,which included
gestational age at booking ,preconceptal folic acid intake, Hyperemesis
gravidarum, pre-eclampsia. Abruptio placentae, premature labor has been
watched for carefully in these women, for they predispose to poor drug intake
and seizures.
Screening for foetal characters in the first, second and third trimester. To
watch for neural tube defects in the first trimester. Alpha foetal protein assay
was done as and when required. In the second trimester targeted anomaly scan
was done and looked for major defects which include cardiac defects, and
urogenital defects. In the third trimester, to look for IUGR, birth hypoxia,
oligohydramnios, and other congenital anomalies, to asses the adequacy of
liquor, congenital anomalies, birth weight.
Mode of delivery:
Pregnancy outcome assessed spontaneous loss before 20 weeks of
gestation foetal still births after 20weeks, live births. Premature delivery was
defined as delivery before gestational week 37, and prolonged pregnancy as
lasting longer than 42 weeks
Whether the patient underwent induced or spontaneous labour,
instrumentation during labour, elective or emergency caesarian section. Types
of anaesthesia and their mode of administration looked for.
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Seizureoutcome in the postnatal period:
Patients in the postnatal period are monitored for the increased seizure
frequency because of the increased stress of the postnatal period and sleep
deprivation and motivated for regular drug intake.
FOETAL OUTCOME :
Apgar score at 1minute,5minutes, birth weight,head circumference ,
major and minor congenital anomalies , specific drug related abnormalities are
assesed. Vitamin K is given for all babies after delivery. Small-for-
gestational-age newborns are defined when they are below the tenth
percentile when adjusted to the gestational age and sex for the normal
population. Infants with birth weight <2,500 g were considered to have low
birth weight. Major malformations were defined as structural abnormalities
with surgical,medical, or cosmetic importance and were identified by the
pediatrician, who examined the infants at birth and at discharge from the
hospital.
To provide adequate breast feeding and neonatal care and to monitor for
feeding difficulties.
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RESULTS
DEMOGRAPHIC PROFILE :
The mean age of the patient was 25.09,maximum age was 39.75% of
them had prenatal counseling before their pregnancy
Table – 1 MATERNAL AGE
TABLE – 2 PARITY
Among 100 pts examined 52% were primigravida,48% multigravida..
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TABLE- 3 EDUCATIONAL STATUS
On viewing their educational status, 30 % of them were found to be
illiterate,54 % attained primary education, 11% secondary education ,only 5
% reached upto college.
TABLE - 4 WORKING STATUS
Most of them were home makers constituting about 92% ,8% of them
were working women.
TABLE -5 CAUSES FOR SEIZURES
Among 100 patients about 47 of them had either CVT, active
granuloma,calcified lesions, benign tumors, and 53 of them were idiopathic.99
had a normal neurological examination,one had a left hemiparesis with
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hemiatrophy.53had a normal imaging either by CT or MRI and 47 had some
abnormality on neuroimaging.The EEG was normal in 42,abnormal in 58.
ETIOLOGY IDIOPATHIC 53 ACQUIRED 47
NEUROLOGICAL
EXAMINATION NORMAL99
LEFT -
1HEMIPARESSIS
IMAGING NORMAL 53 ABNORMAL 47
EEG NORMAL 42 ABNORMAL58
TABLE – 6 PRECONCEPTUAL FOLIC ACID INTAKE
Folic acid was taken by most of them preconceptal amounting to 96
%. 4% of them never consumed folic acid prior to pregnancy.
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TABLE-7 COMPLICATIONS
One women developed GDM during her pregnancy course,2 of them
developed pregnancy induced hypertension. 70% of the pregnant women with
epilepsy were suffering from anemia. (hyperemesis gravidarum) occured more
frequently in these women , which made them difficult to take oral
medications.
COMPLICATIONS
70
1 2
27
0
10
20
30
40
50
60
70
80
ANEMIA DM HT NIL
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TABLE – 8 MATERNAL SEIZURE PROFILE AND ANTIEPILEPTIC
DRUG INTAKE
On viewing their epileptic diary it was found that 81% had generalised
tonic clonic seizures,12 % complex partial seizures,2 % simple partial seizures
with secondary generalisation,5 % complex partial seizures with secondary
generalisation
81%
12%
2%
5%
GTCS CPS SPWSG CPWSG
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TABLE -9 ANTEPARTUM SEIZURE FREQUENCY
83 of 100 patients had good seizure control prior to pregnancy .10 of
these 83 had increased seizures during pregnancy . 17 of those 100 who had
poor seizure control prior to pregnancy also noted an increase in seizure
frequency during pregnancy .1% developed status epilepticus. Age of onset
of epilepsy , duration , and etiology had no relationship to seizure occurrence.
SEIZURE FREQUENCY
Yes
17%
No
83%
Yes No
No 
73% 
Yes 
27% 
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TABLE-10 AED MONOTHERAPY
Out of 100 , 72 of them on monotherapy with either phenytoin 42,
carbamazepine 23, and sodium valproate 7.
DRUGS FREQUENCY PERCENT
PHENYTOIN
CARBAMAZEPINE
SODIUM VALPROATE
TOTAL
42
23
7
72
58.33
31.94
9.72
100.0
AED MONOTHERAPY
42
23
7
72
0
10
20
30
40
50
60
70
80
PHENYTOIN CARBAMAZEPINE SODIUM VALPROATE TOTAL
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TABLE-11 AED INTAKE ON TWO DRUG REGIMEN
Out of 100 , 20 on two drug combinations with CBZ+SVP -5,
CBZ+PHT-1, SVP +CBZ-3,PHT+SVP-7,PHT+CBZ-4.
DRUG
COMBINATION
FREQUENCY PERCENT
CBZ+SVP
CBZ +PHT
SVP+CBZ
PHT+SVP
PHT+CBZ
TOTAL
5
1
3
7
4
20
25.0
5.0
15.0
35.0
20.0
100.0
TABLE - 12 : AED INTAKE 3 DRUG REGIMEN
DRUG
COMBINATION
FREQUENCY PERCENT
CBZ+SVP+PHT
CBZ+PHT+PHB
CBZ+PHT+SVP
PHT+SVP+LEV
CBZ+SVP+LEV
TOTAL
2
1
1
2
2
8
25.0
12.5
12.5
25.0
25.0
100.0
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TABLE- 13 :NO OF DRUGS
Out of 100 patients 72% on monotherapy, 20% on two drug
regimen,8% on polytherapy.
The dose of aeds ranged from 200mg -400mg for phenytoin,
400mg -600mg for sodium valproate), 400mg -1200mg for carbamazepine)
4 of them on 100mg of phenytoin,
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Table– 14 : CHANGE OF_DRUG
About 21% had a change in the drug dosage during their pregnancy and
79% maintained their prepregnancy drug dosage .
Frequency Percent Valid Percent
Cumulative
Percent
Valid Yes 21 21.0 21.0 21.0
No 79 79.0 79.0 100.0
Total 100 100.0 100.0
Ultrasound evaluation done under high resolution during the first
trimester did not reveal any abnormality in any of them.2 had neural tube
defects during the third trimester.5 of them were diagnosed with congenital
malformations after delivery.
PREGNANCY OUTCOME
DURATION OF DELIVERY
87% had an uveventful course throughout their pregnancy and delivered
at term.9% had preterm delivery.80% had normal vaginal delivery at term.4%
had difficult labour and delivered by forceps, 3 had abortion, one of them had
still birth ,and all of them had good seizure control during pregnancy 6%
emergency LSCS,6% had elective LSCS. because of foetal distress. 12%
underwent LSCS for obstetrical indication.The indication for emergency
LSCS was difficult labour with failed induction, foetal distress, a big baby.
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Table– 15
Frequency Percent ValidPercent
Cumulative
Percent
Term 87 91.0 91.0 91.0
Preterm 9 9.0 9.0 100.0
Total 96 100.0 100.0
MODE OF DELIVERY
Frequency Percent
Natural 80 80.0
Forceps 4 4.0
LSCS_EMER 6 6.0
LSCS_ELEC 6 6.0
Abortions 3 3.0
Still Births 1 1.0
Total 100 100.0
 
80%
4%
6%
6%
3%1%
Natural Forceps LSCS_EMER LSCS_ELEC Abortions Still Births
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4% developed postpartum haemorrhage none of them had antepatum
haemorrhage. 4% developed postpartum seizures.
FOETAL OUTCOME
5 had apgar score of less than 5 at l minute.which improved to 7 or
more at 5 minutes.
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25%had low birth weight of below 2.5kg, 75% had a normal birth weight
between 2.5 kg to 3.5kg.
.AED DRUG THERAPY AND CM
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PREGNANCY COMPLICATIONS AND CM
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SEIZURE TYPE AND CM
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MODE OF DELIVERY IN PATIENTS WITH CM
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CONGENITALMALFORMATIONS TABLE 21
COMPLICATION
S AGE
PARIT
Y
FOLIC
ACID
GESTA
TIONA
L AGE
SEIZUR
E TYPE
AED
INTAKE
AED
DOS
AGE
DELI
VERY
MODE OF
DELIVERY
POS
TPA
RTU
M
APG
AR
1MT
AP
GA
R
5M
T
BIR
TH
WEI
GHT
DERMOID CYST 22 PRIMI YES 12 GTCS PHT 300MG TERM NATURAL NO 5 8 2.75
VSD 24 PRIMI YES 14 GTCS CBZ 1000MG TERM NATURAL NO 7 9 3
ASD 23 PRIMI YES 13 GTCS PHT 300MG TERM NATURAL NO 6 8 3
ARNOLD CHIARI 26 PRIMI YES 12 CPSWS PHT 300MG
PRET
ERM NATURAL NO 5 7 2.5
MENINGOCELE 25 MULTI YES 12 GTCS PHT/SVA 200/600 TERM NATURAL NO 6 7 2.75
MYELOMENING
OCELE 26 PRIMI YES 20 SPWSG
SVA
/CBZ 200 TERM NATURAL NO 6 9 2.5
SPINA BIFIDA 33 PRIMI YES 14 CPS PHT/CBZ/ VPA
200/4
00/40
0
TERM NATURAL NO 5 7 2.6
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 Malformations occurred in 6% of primigravida, and 1% of multigravida.
72 % out of 100 patients were on monotherapy with 42 % on phenytoin ,23%
on carbamazepine and 7% on sodium valproate.The incidence of congenital
malformations was 3 in those on phenytoin, 1 in carbamazepine.
20 of 100 patients were on two drug regimen In SVP+CBZ
combination CM occured in 1, with PHT+SVP is 1. Among 8 of them on
polytherapy one had malformation . The relation between drug regimen and
congenital malformations is 5.6%(4 of 72) on monotherapy, 10.0%(2 of 20)
on two drug regimen,12.5% (1 of 8) on polytherapy. Among those who
presented with malformations 4 had generalised tonic clonic seizures,one with
Complex partial seizures, one simple partial with secondary generalisation,
one had complex partial seizures with secondary generalisation. All of them
had preconceptal intake of folic acid and had no contributory risk factors like
gestational diabetes , preeclampsia, or eclampsia.
Children with CM were delivered per vaginum naturally. 6 of the
neonates with congenital malformations delivered at term ,1 at preterm. The
major congenital malformations observed are 1 had dermoid cyst, 3 had neural
tube defects, Arnoldchiari mal formation, meningocele, meningomyelocele,
spinabifida. 2 with cardiac disorders Ventricular septal defect, atrial septal
defect detected 1 month after delivery.
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 All the neonates had a good apgar score at 1 and 5 minutes despite their
malformations.But feeding difficulties were encountered in 2 neonates with
cardiac malformations.1 baby had an N ICU admission.
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DISCUSSION
Women with epilepsy usually fear the risk of pregnancy complications
and birth defects would be higher because of seizures and because her baby
will be exposed to antiepileptic drugs. However, many women with epilepsy
and their treating physicians believe these risks to be higher than they really
seemed to be.
Our study was mainly done in WWE who took AEDs prior to and
during pregnancy.Consanguinous parentage was excluded from our study to
minimise the role of genetic factors on the foetal outcome.
According to Richmond et al [28] there was a increased risk of PIH
[< 0.5] in WWE. The rate of preeclampsia was not significantly increased in a
prospective study of 179 pregnancies of WWE in singleton pregnancy at
finland.[46] In A Swedish study by Christina philo etal done on 1207[29]
women taking AEDs in pregnancy found a significant increase in the incidence
of pre-eclampsia (OR 1.66, 95% - CI 1.43–1.89). There was no increased risk
of preeclampsia or GDM in our study population.
The EURAP registry[14] on 1882 WWE recorded seizure freedom in
58% of participants during pregnancy. When first trimester seizure activity
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was used a reference, 64% had no change in the second and third trimester,
16% improved, while only 17% deteriorated. The Australian Register by
(Vajda et al)[47] found that an year of seizure freedom prior to conception
reduced the pregnancy risks of having seizures by 50-70%. But in our study
27 % had an increase in their seizure frequency in the antepartum period . In
17 of them it was either because of poor drug compliance, fear of intake of
antiepileptic drugs causing congenital malformations in the child and one
among them developed status epilepticus , not able to procure drugs because
of their shift of residence, but some of them developed seizures despite good
drug compliance.73% had no increase in seizure frequency. There was no
relationship between the seizure duration and frequency of seizures.The
increase in frequency occurred both in generalized and partial epilepsy groups.
Walker et al [48] reported that Women with good seizure control (e.g.
seizure free for 2–5 years) may be eligible to stop or reduce their medication
prior to pregnancy, and women taking more than one AED may be considered
a trial of monotherapy, if they have normal neurological examination/IQ, EEG
and neuroimaging, for the risk of getting a seizure is much lower. In our
study 27% had a change in medication to monotherapy because of good
seizure control.All of them had a normal neurological examination and EEG.
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 Epileptic pregnant women have a higher induction rate . This has been
reported with two previous studies in which 33% and 19% were induced, but
contrary to the finding in a study from Japan [49] where no difference was seen.
According to guidelines in Norway and England [50], epilepsy is not an
indication for induction in uncomplicated pregnancies. The induction rate was
low in our women 4 of them were induced and delivered by forceps, and
most of them had spontaneous vaginal delivery.12% of 100 patients, delivered
by caesarian section, 6 by elective, 6 by emergency LSCS due obstetrical
causes.
An increase in vaginal bleeding during late pregnancy and delivery, has
been reported with previous studies (Pennell; Pilo et al.)[51, 29] but in our study
group 4 patients developed PPH. Alterations in vitamin K metabolism may
also be a causal factor (Crawford; Pilo et al.) [52,29] possibly associated with use
of enzyme-inducing AEDs.
EURAP registry[14] data regarding the impact of seizures on pregnancy
outcome in 1956 WWE, had a stillbirth rate of (1.5%) which is higher than
that in the general population of 0.5% Earlier reports have suggested higher
mortality in infants born to mothers with epilepsy; Hiilesmaa et al.; Meador et
al[ 35,37,31) due to poor control of maternal seizure LaJoie & Moshe[10,35]. There
was 1 abortion, 3 still births in our study. No neonatal deaths were seen.
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FOETAL OUTCOME
Low birth weight and low apgar score was seen in epileptic mothers
exposed to AEDs in the literature.[57,58]. In our study low birth was seen in
25% of the mothers exposed to AEDs. 5 of 100 neonates had an apgar score of
less than 5 at 1minute which improved to 7 or more at 5 minutes, leading to
favourable birth outcomes in our study group.
The U.K. registry(39) reported a higher malformation rate with VPA,
5.9% (4.3–8.2%; 95% CI), than with CBZ (2.3% [1.4–3.7%]) or LTG (2.1%
[1.0–4.0%]).The types of congenital malformations found in pregnancies
exposed to monotherapy with either carbamazepine, valproate, and phenytoin
were similar to those previously reported abnormalities. An American
Academy of Neurology Practice Parameter (25) concluded the increased the
risk for major congenital malformations associated with AED intake during the
first trimester and with polytherapy.
The incidence of malformations for monotherapy was for
carbamazepine 4.6% , lamotrigine 2.9%, phenobarbitol 4.9% , phenytoin 7.4%
and valproate 10.7% , with VPA having a higher dosage related relation either
as monotherapy or polytherapy. .[13,42,53]. The rate of congenital malformations
is 2 to 3% in the general population, reported rates in offspring of women with
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epilepsy ranged from 1.25 to 11.5%, with the combined estimates yielding a
rate of 4 to 6%. Previous studies by reports [39,42,51,53) reported an increase in
congenital malformations. In our study 7 of 100 WWE delivered a child with
congenital malformations. In monotherapy group it was 7.142% (3 of 42) on
therapy with phenytoin,4.34% (1 of 23) on carbamazepine. On 2 drug regimen
it was 1 with SVP+PHT,1 with CBZ+SVP. In polytherapy group it was
12.5%(1 of 8). CM risk is 5.6% on monotherapy ,10.0% on two drug
regimen,12.5% on polytherapy.
The congenital malformations in our group are Neural tube defects,
cardiac malformations, dermoid cyst. The relative risk of malformations was
higher with monotherapy and polytherapy in our epileptic pregnant women.
Studies have shown that folic acid is effective in reducing malformations in
the general population, but not in AED-exposed pregnancies. Studies have
revealed an association between CBZ exposure in utero and NTDs. (54, 55, 56)
NTDs occur in 6/10,000 pregnancies. Lingh et al has associated spinabifida
aperta as the specific NTD associated with VPA & CBZ exposure. (55)
Neural tube defects, can be prevented if folic acid is initiated
pre-conceptually [40,41], and every effort must be taken to improve folic acid
supplementation in women with epilepsy , and majority of our patients were
on preconceptual folic acid including those with congenital malformation .In
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ourstudy, preconceptal folic acid supplementation was higher in AED-treated
pregnancies, especially when treated with valproate or polytherapy.
A prospective multicenter, observational study revealed that fetal
exposure to valproate resulted in significantly lower IQ at age 3 compared to
carbamazepine, lamotrigine, or phenytoin. The effect of valproate on lowering
fetal IQ was dose dependent. In our study the dose of valproate was
significantly reduced without affecting the seizure frequency.[31]
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CONCLUSION
1. Most of our pregnant patients had good seizure control before and
during pregnancy.
2. In those with poor seizure control prior to pregnancy had improved
seizures during pregnancy, due to stringent monitoring and care.
3. Status epilepticus occurred in one patient.
4. Most of our patients had successful vaginal delivery, in those who had
caesarian section it was done for non neurological indication like
cephalopelvic disproportion, foetal distress.
5. During postpartum period only four of them developed seizures .
The incidence of congenital malformations, CM risk is 5.6% on
monotherapy,10.0% on two drug regimen,12.5% on polytherapy. There was no
neonatal deaths.
It is important to educate pregnant women with epilepsy for proper
planning of their pregnancies , for preconceptal folic acid intake, AED intake
during the course of pregnancy, and also monitor with high resolution
ultrasound for the detection of congenital malformations.
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16 PRIMI ILLETERATE HW YES GTCS CBZ 10 YES 800 N0 NO N TERM Natural O 2 N 5 7 2
18 PRIMI ILLETERATE HW YES CPWSG CBZ PHT 12 NO 600 200 N0 NO N TERM Natural O 2 N 6 7 2
23 PRIMI ILLETERATE HW YES GTCS CBZ 14 YES 1200 N0 NO N TERM Natural O 2 N 5 8 2
19 PRIMI ILLETERATE HW YES GTCS CBZ 14 YES 600 N0 NO N TERM natural outlet forceps 1 2 N 7 8 2
30 PRIMI PRIMARY HW YES GTCS CBZ SVP PHT 10 NO 600 200 200 N0 YES N TERM N O 1 N 7 8 2
22 MULTI PRIMARY HW YES GTCS CBZ 12 YES 400 N0 N0 N TERM emergency O 2 N 7 8 2
27 MULTI PRIMARY HW YES CPWSG SVP CBZ 10 NO 600 N0 NO N TERM natural O 2 N 5 7 2
26 PRIMI PRIMARY HW YES GTCS SVP 10 NO 400 N0 NO N TERM natural O 2 N 6 7 2
21 PRIMI PRIMARY HW YES GTCS CBZ 16 NO 600 N0 NO N TERM natural O 2 N 5 8 2
26 MULTI PRIMARY HW NO GTCS PHT CBZ SVP 20 NO 200 400 600 N0 NO N TERM natural O 2 N 6 8 2
21 MULTI PRIMARY HW YES CPS CBZ 16 NO 200 N0 YES N TERM natural O 2 N 5 7 2
34 MULTI PRIMARY HW YES GTCS PHT 14 YES 300 N0 NO N PRETERM Lscs Emergency O 2 N 7 8 2
22 MULTI PRIMARY HW NO GTCS CBZ 12 YES 600 N0 NO N TERM natural O 1 N 6 8 2
22 PRIMI PRIMARY HW YES GTCS PHT SVP 12 NO 200 400 N0 NO N TERM natural O 2 N 6 8 1
21 MULTI PRIMARY HW YES GTCS CBZ 12 NO 1000 N0 NO n TERM natural 2 2 N 5 7 2
19 PRIMI PRIMARY HW YES GTCS PHT 14 NO 200 N0 NO N TERM natural 2 2 N 5 7 2
24 MULTI PRIMARY HW YES CPS PHT 13 NO 200 N0 NO N TERM previous O 1 N 5 7 2
23 PRIMI SECONDARY HW YES GTCS PHT 14 NO 200 N0 NO N TERM natural O 2 N 6 7 2
19 PRIMI SECONDARY HW YES GTCS PHT 10 NO 300 N0 YES N TERM LSCS Emer O 2 N 7 8 2
33 PRIMI SECONDARY HW YES GTCS CBZ PHT PB 12 YES 400 200 30 N0 NO N TERM Natural O 2 N 6 7 1
25 PRIMI COLLEGE HW YES CPS PHT 16 YES 200 N0 NO N TERM Natural O 2 N 2
26 PRIMI PRIMARY HW YES GTCS SVP 12 YES 200 N0 YES N TERM Natural O 1 N 6 7 2
26 PRIMI PRIMARY HW YES GTCS CBZ SVP 14 NO 600 400 N0 YES N TERM Natural O 2 N 5 7 2
27 MULTI ILLETERATE HW YES GTCS PHT 12 NO 200 HYDRAMNIOS NO N TERM Natural O 2 N 6 8 2
23 PRIMI ILLETERATE WORK YES GTCS CBZ 12 NO 400 N0 NO N TERM Natural O 2 N 6 8 2
25 MULTI ILLETERATE HW YES GTCS PHT SVP 16 NO 200 400 HT NO N TERM Natural 1 1 N 7 8 2
26 MULTI PRIMARY HW YES GTCS PHT 12 NO 200 HT YES N TERM Natural 2 2 N 7 8 2
21 PRIMI PRIMARY HW YES GTCS CBZ 10 YES 600 N0 YES N TERM Natural O 2 N 6 7 2
21 MULTI PRIMARY HW YES GTCS PHT 12 NO 200 N0 NO N TERM Natural O 2 N 5 7 2
23 MULTI PRIMARY HW YES GTCS CBZ SVP 10 NO 600 200 N0 YES N TERM Natural O 2 N 6 8 2
21 PRIMI SECONDARY HW YES CPWSG PHT 12 NO 200 N0 YES N TERM
Natural 
Forceps 
Delivery
O 2 N 3 7 2
23 PRIMI PRIMARY HW YES GTCS PHT 14 YES 200 N0 NO N TERM Natural O 1 N 6 8 2
23 PRIMI ILLETERATE HW YES GTCS PHT 10 YES 100 N0 NO N TERM natural O 2 N 5 7 2
22 PRIMI ILLETERATE HW YES SPWSG SVP CBZ 13 NO 400 400 N0 NO N TERM natural O 2 N 6 7 1
25 MULTI COLLEGE WORK YES GTCS PHT 12 YES 200 N0 NO N TERM lscs Emer O 2 N 7 8 2
23 PRIMI COLLEGE HW YES GTCS PHT 14 NO 200 N0 NO N TERM natural O 1 N 5 7 1
20 MULTI SECONDARY HW YES GTCS PHT 24 NO 200 N0 NO N TERM lscs emer 1 2 N 6 8 2
21 PRIMI SECONDARY HW YES CPSWG PHT 20 NO 200 N0 NO N TERM natural 2 2 N 7 8 2
26 PRIMI PRIMARY HW YES GTCS CBZ SVP 8 NO 1200 400 N0 YES N TERM Natural O 2 N 8 9 2
27 PRIMI PRIMARY HW YES GTCS PHT 10 YES 200 N0 YES N TERM Natural O 1 N 6 8 2
20 PRIMI PRIMARY HW YES GTCS PHT 12 YES 300 N0 YES N TERM Natural O 1 N 7 7 2
28 MULTI PRIMARY HW YES GTCS PHT 14 YES 300 N0 NO N PRETERM Natural O 2 N 5 7 2
21 PRIMI PRIMARY HW YES GTCS PHT 10 YES 200 N0 YES N TERM Natural O 2 N 5 7 2
26 MULTI PRIMARY HW YES CPS PHT 12 YES 200 N0 YES N TERM Natural O 2 N 6 8 1
36 PRIMI SECONDARY HW YES GTCS CBZ SVP 14 YES 600 400 N0 NO N TERM Natural O 2 N 6 8 2
27 PRIMI ILLETERATE HW YES GTCS CBZ SVP LEV 20 NO 1000 200 1000 N0 YES N TERM Natural O 1 N 6 8 2
21 PRIMI ILLETERATE WORK YES GTCS PHT 14 NO 100 N0 NO N TERM Natural 2 2 N 7 8 2
30 MULTI ILLETERATE WORK YES GTCS CBZ SVP PHT 12 NO 200 400 100 GDM NO N TERM Natural O 2 N 5 7 2
21 MULTI ILLETERATE HW YES CPS CBZ 12 NO 400 N0 YES N TERM forceps delivery O 2 N 5 7 2
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31 MULTI ILLETERATE HW YES CPS PHT 12 NO 200 N0 NO N TERM natural O 2 N 6 8 2
26 MULTI ILLETERATE HW YES GTCS SVP 10 NO 600 N0 NO N TERM natural O 2 N 5 7 2
26 MULTI COLLEGE HW YES GTCS CBZ SVP LEV 10 NO 400 200 1000 N0 YES N TERM natural O 1 N 6 9 2
21 PRIMI SECONDARY HW YES GTCS CBZ 12 YES 200 N0 NO N TERM natural O 2 N 7 8 2
29 MULTI SECONDARY HW YES CPS PHT 12 YES 200 N0 NO N TERM natural O 2 N 7 8 2
28 PRIMI PRIMARY HW YES GTCS PHT SVP 12 YES 30 400 N0 NO N TERM emergencyLSCS 1 1 N 7 8 2
27 MULTI ILLETERATE WORK YES GTCS SVP 16 YES 600 N0 NO N TERM natural O 2 N 5 7 2
18 PRIMI ILLETERATE HW YES GTCS CBZ 12 NO 200 N0 YES N TERM natural O 2 N 5 7 2
27 MULTI ILLETERATE HW YES GTCS PHT 14 YES 200 N0 YES N TERM natural O 2 N 7 8 2
21 PRIMI ILLETERATE HW YES CPS CBZ 12 YES 200 N0 YES Nomal TERM natural 2 1 N 5 7 2
24 PRIMI ILLETERATE HW YES GTCS CBZ 12 NO 300 N0 NO N TERM natural O 2 N 5 7 1
26 PRIMI ILLETERATE HW YES CPWSG PHT 12 NO 200 N0 NO 30 -32 
weeks TERM natural O 2 N 6 7 1
25 MULTI SECONDARY HW YES GTCS PHT 12 NO 300 N0 NO normal TERM PLSCS O 2 N 6 7 2
21 MULTI PRIMARY WORK YES GTCS PHT 16 NO 200 N0 NO N TERM PLSCS O 2 N 5 7 2
25 PRIMI PRIMARY HW YES CPS CBZ 12 NO 400 N0 NO Normal TERM natural O 1 N 7 8 2
22 MULTI PRIMARY HW YES SPWSG PHT 12 NO 200 N0 NO Normal TERM natural O 2 N 6 9 2
26 PRIMI PRIMARY HW YES GTCS PHT SVP 12 NO 200 400 N0 NO Normal TERM natural O 2 N 6 8 2
20 PRIMI PRIMARY HW YES GTCS PHT CBZ 12 NO 200 1000 N0 NO Normal TERM natural O 2 N 5 7 2
23 MULTI PRIMARY HW YES GTCS PHT CBZ 12 YES 200 1000 N0 NO Normal TERM natural O 1 N 5 7 2
27 MULTI PRIMARY HW YES GTCS CBZ 10 NO 200 800 N0 NO Normal PRETERM ELSCS O 2 N 2 7 2
29 MULTI PRIMARY HW YES CPS CBZ 10 NO 400 N0 NO Normal TERM natural O 1 N 5 7 2
30 MULTI PRIMARY HW YES GTCS PHT 3 14 NO 200 600 N0 NO Normal TERM natural O 2 N 6 8 2
23 PRIMI PRIMARY HW YES GTCS PHT 20 NO 200 N0 YES Normal TERM natural O 1 N 6 7 2
20 PRIMI SECONDARY HW NO GTCS PHT SVP 22 YES 200 400 N0 NO Normal PRETERM forceps delivery O 2 N 3 8 2
24 PRIMI PRIMARY WORK YES GTCS PHT 12 NO 200 N0 YES Normal TERM natural O 2 N 7 9 2
35 PRIMI PRIMARY HW YES GTCS PHT 12 NO 200 N0 NO Normal TERM ELSCS O 1 N 6 7 2
31 MULTI PRIMARY HW YES CPS CBZ SVP 12 NO 400 200 N0 NO Normal TERM natural O 1 N 6 7 2
19 PRIMI PRIMARY HW YES GTCS SVP 12 NO 200 N0 NO Normal TERM natural O 2 N 7 8 2
28 MULTI COLLEGE HW NO GTCS PHT 12 YES 200 N0 NO Normal TERM natural O 2 N 7 7 2
32 MULTI PRIMARY HW YES GTCS PHT 20 NO 300 N0 NO Normal TERM natural O 1 N 6 7 2
39 MULTI PRIMARY HW YES GTCS PHT CBZ 14 NO 300 200 N0 NO Normal TERM natural O 2 N 7 8 2
23 MULTI ILLETERATE HW YES CPS CBZ 13 NO 600 N0 NO Normal TERM natural O 1 N 7 8 2
26 MULTI ILLETERATE HW YES CPS CBZ 15 NO 1000 N0 NO Normal TERM ELSCS O 2 N 2 8 2
24 MULTI ILLETERATE HW YES GTCS PHT 16 NO 200 N0 NO Normal TERM natural 2 2 N 7 8 2
27 MULTI ILLETERATE HW YES GTCS PHT SVP 22 NO 200 200 N0 NO Normal TERM natural 2 2 N 6 8 2
28 MULTI ILLETERATE HW YES GTCS PHT 24 NO 300 N0 NO Normal PRETERM natural O 2 N 6 8 2
33 MULTI ILLETERATE HW YES CPS CBZ 12 NO 400 N0 NO Normal TERM natural 2 1 N 7 8 2
25 MULTI PRIMARY HW YES GTCS PHT SVP LEV 10 NO 100 400 1000 N0 NO Normal TERM natural O 2 N 2 7 2
29 PRIMI ILLETERATE HW YES GTCS PHT 13 NO 200 N0 NO Normal TERM natural O 2 N 5 7 2
22 MULTI ILLETERATE HW YES GTCS SVP 22 NO 400 N0 NO Normal PRETERM natural O 2 N 6 7 2
25 PRIMI ILLETERATE HW YES GTCS PHT SVP LEV 20 NO 100 600 500 N0 NO Normal TERM natural O 2 N 5 7 2
23 PRIMI PRIMARY HW YES GTCS PHT 14 NO 200 N0 NO Normal TERM natural O 1 N 5 7 2
26 PRIMI PRIMARY WORK YES GTCS PHT 12 NO 200 N0 NO Normal TERM natural O 2 N 5 7 2
32 MULTI PRIMARY HW YES CPS CBZ 12 NO 400 N0 NO Normal PRETERM natural 2 2 N 6 8 2
20 PRIMI PRIMARY HW YES GTCS PHT CBZ 12 NO 400 200 N0 NO Normal TERM natural O 2 N 6 8 2
27 MULTI PRIMARY HW YES GTCS PHT 12 NO 200 N0 NO Normal TERM natural O 2 N 6 8 2
33 PRIMI PRIMARY HW YES GTCS PHT SVP 12 NO 200 400 N0 NO Normal PRETERM natural O 2 N 7 9 2
31 PRIMI PRIMARY HW YES GTCS PHT 12 NO 200 N0 NO Normal TERM natural O 2 N 7 9 2
26 PRIMI PRIMARY HW YES GTCS SVP 12 NO 200 N0 NO Normal PRETERM natural O 1 N 6 8 2
25 PRIMI PRIMARY HW YES GTCS PHT 10 NO 200 N0 NO Normal TERM natural O 2 N 6 8 2
23 MULTI ILLETERATE HW YES SPWSG PHT 14 NO 200 NO NO Normal TERM natural 1 7 N 8 9 2
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KEYS FOR MASTER CHART
POSTPARTUM PERIOD
1 - PPH
2 - SEIZURES
0 - NO COMPLICATIONS
BWT (BIRTH WEIGHT)
1 - <2.5KG
2 - >2.5KG
CM (CONGENITAL MALFORMATIONS)
1 - YES
2 - NO



